Synergistic Combination of Cytotoxic Chemotherapy and Cyclin Dependent Kinase 4/6 Inhibitors in Biliary Tract Cancers
Authors:
- Mansi AroraMAMansi Arora
- James M. BogenbergerJBJames M. Bogenberger
- Amro M. AbdelrahmanAAAmro M. Abdelrahman
- Jennifer YonkusJYJennifer Yonkus
- Roberto Alva-RuizRARoberto Alva-Ruiz
- Jennifer L. LeitingJLJennifer L. Leiting
- Xianfeng ChenXCXianfeng Chen
- Pedro Luiz Serrano Uson JuniorPedro Luiz Serrano Uson Junior
- Chelsae R. DumbauldCDChelsae R. Dumbauld
- Alexander T. BakerAlexander T. Baker
- Scott I. GambSGScott I. Gamb
- Jan B. EganJEJan B. Egan
Preprint
Abstract
Biliary tract cancers (BTCs) are uncommon but highly lethal gastrointestinal malignancies. Gemcitabine/cisplatin is a standard-of-care (SOC) systemic therapy, but has a modest impact on survival and harbor toxicities including myelosuppression, nephropathy, neuropathy and ototoxicity. While BTCs are characterized by aberrations activating the cyclinD1-CDK4/6-CDKN2A-RB pathway, clinical use of CDK4/6 inhibitors as monotherapy is limited by lack of validated biomarkers, diffident pre-clinical efficacy and development of acquired drug resistance. Emerging studies have explored therapeutic strategies to enhance the anti-tumor efficacy of CDK4/6 inhibitors by combination with chemotherapy-regimens but their mechanism of action remains elusive. Here, we report in vitro and in vivo synergy in BTC models, showing enhanced efficacy, reduced toxicity and better survival with a combination comprising gemcitabine/cisplatin and CDK4/6 inhibitors. Furthermore, we demonstrated that abemaciclib monotherapy had only modest efficacy due to autophagy induced resistance. Notably, triplettherapy was able to potentiate efficacy through elimination of the autophagic flux. Correspondingly, abemaciclib potentiated RRM1 reduction, resulting in sensitization to gemcitabine. Conclusions: As such, these data provide robust pre-clinical mechanistic evidence of synergy between gemcitabine/cisplatin and CDK4/6 inhibitors, and delineate a path forward for translation of these findings to preliminary clinical studies in advanced BTC patients.Keywords
All Related Versions
- Published version: Hepatology, 75 (1), 43.
This publication has 46 references indexed in Scilit:
- Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabineInvestigational New Drugs, 2014
- Autophagy Inhibition Augments the Anticancer Effects of Epirubicin Treatment in Anthracycline-Sensitive and -Resistant Triple-Negative Breast CancerClinical Cancer Research, 2014
- The Residual Tumor Autophagy Marker LC3B Serves as a Prognostic Marker in Local Advanced Breast Cancer after Neoadjuvant ChemotherapyClinical Cancer Research, 2013
- CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, “fueling” tumor growth via paracrine interactions, without an increase in neo-angiogenesisCell Cycle, 2012
- Modification of the DNA Damage Response by Therapeutic CDK4/6 InhibitionJournal of Biological Chemistry, 2012
- CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapyCell Cycle, 2012
- Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian CancerClinical Cancer Research, 2011
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerNew England Journal of Medicine, 2010
- Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trialsBritish Journal of Cancer, 2007
- Biliary Tract CancersNew England Journal of Medicine, 1999